Essex LLC Takes $2.67 Million Position in Xencor, Inc. (NASDAQ:XNCR)

Essex LLC acquired a new position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 132,661 shares of the biopharmaceutical company's stock, valued at approximately $2,668,000. Essex LLC owned approximately 0.22% of Xencor as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in XNCR. Diversified Trust Co lifted its position in shares of Xencor by 4.5% during the 1st quarter. Diversified Trust Co now owns 13,059 shares of the biopharmaceutical company's stock valued at $289,000 after buying an additional 563 shares in the last quarter. Texas Permanent School Fund Corp increased its stake in Xencor by 1.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 53,277 shares of the biopharmaceutical company's stock worth $1,179,000 after buying an additional 690 shares during the period. Linden Thomas Advisory Services LLC boosted its holdings in Xencor by 1.6% in the second quarter. Linden Thomas Advisory Services LLC now owns 43,643 shares of the biopharmaceutical company's stock valued at $826,000 after purchasing an additional 699 shares during the period. Baillie Gifford & Co. grew its position in shares of Xencor by 3.3% during the second quarter. Baillie Gifford & Co. now owns 23,530 shares of the biopharmaceutical company's stock worth $445,000 after buying an additional 744 shares in the last quarter. Finally, Louisiana State Employees Retirement System lifted its position in shares of Xencor by 3.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 31,000 shares of the biopharmaceutical company's stock worth $587,000 after purchasing an additional 900 shares during the last quarter.

Wall Street Analysts Forecast Growth

XNCR has been the subject of a number of analyst reports. Royal Bank of Canada upped their price objective on shares of Xencor from $31.00 to $34.00 and gave the stock an "outperform" rating in a research report on Thursday, September 26th. JPMorgan Chase & Co. reduced their price target on shares of Xencor from $30.00 to $27.00 and set an "overweight" rating on the stock in a research report on Wednesday, July 31st. Wedbush reiterated an "outperform" rating and set a $34.00 price objective on shares of Xencor in a research note on Monday, September 9th. Finally, BMO Capital Markets restated an "outperform" rating and set a $32.00 price objective on shares of Xencor in a research note on Tuesday, August 6th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $34.78.

Xencor Price Performance

Shares of NASDAQ:XNCR traded up $0.42 during midday trading on Friday, reaching $21.78. 253,424 shares of the company's stock were exchanged, compared to its average volume of 461,001. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.92 and a current ratio of 6.92. The company's 50 day simple moving average is $18.99 and its two-hundred day simple moving average is $20.10. The firm has a market capitalization of $1.52 billion, a PE ratio of -7.54 and a beta of 0.67. Xencor, Inc. has a 12 month low of $15.31 and a 12 month high of $26.84.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.25). Xencor had a negative net margin of 132.74% and a negative return on equity of 28.23%. The business had revenue of $16.96 million during the quarter, compared to the consensus estimate of $21.13 million. During the same period in the prior year, the firm earned ($0.37) earnings per share. The business's quarterly revenue was down 62.7% compared to the same quarter last year. Equities research analysts expect that Xencor, Inc. will post -4.11 earnings per share for the current fiscal year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.